{
  "ticker": "JNJ",
  "date": "2024-03-25",
  "lookback_days": 14,
  "fetched_at": "2026-02-13T11:54:56.118002",
  "source": "alpha_vantage",
  "article_count": 2,
  "articles": [
    {
      "title": "Biosimilars lawsuits and settlement updates for Regeneron and Alvotech",
      "summary": "Regeneron has filed a lawsuit against Amgen, alleging patent infringement regarding Amgen's proposed biosimilar of Regeneron's Eylea, after earning US$6.26 billion in US sales in 2022. Meanwhile, Alvotech announced anticipated global market entry dates for its ustekinumab biosimilar, AVT04, following a settlement with Johnson & Johnson, with launches expected in Canada, Japan, and Europe.",
      "url": "https://www.gabionline.net/pharma-news/biosimilars-lawsuits-and-settlement-updates-for-regeneron-and-alvotech",
      "source": "Generics and Biosimilars Initiative",
      "published": "20240322T000000",
      "overall_sentiment_score": 0.101578,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.218202,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.645323
    },
    {
      "title": "Gilead CAR-T cancer therapy capacity to quadruple by 2026",
      "summary": "Gilead Sciences expects to quadruple the production capacity of its CAR-T cancer treatments, Yescarta and Tecartus, by 2026, reaching 24,000 treatments annually without additional investment, due to manufacturing process improvements. The company aims to expand its market share by making these therapies available in more hospitals and reducing turnaround times, despite a recent slowdown in CAR-T revenue growth.",
      "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-car-t-cancer-therapy-capacity-quadruple-by-2026-2024-03-15/",
      "source": "Reuters",
      "published": "20240315T100300",
      "overall_sentiment_score": 0.234039,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.142433,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.631872
    }
  ]
}